As I have stated numerous times MM was DOA. Neither the FDA, UK, or EU has any interest on mild to moderate patients. No EAU from any country will be forthcoming. An approval for S/C will allow doctors to prescribe for moderate as Nader stated.
S/C is where the opportunity exists for our shot at EUA and ultimate approval in the Covid space. Enrollment continues and now we are well above 200 patients. Nader knows the odds are that we will have to fully enroll. We have a high probability of success w this indication but will be into Q1 2021.
Nasdaq Uplist will not happen w/o an accompanying approval. It would be futile to attempt to do so given the current circumstances.
BLA fumbling is an indication to the market that magnifies Nader’s lack of experience and competancy. This was perhaps Nader’s most detrimental blow to the companies credibility and we are consequently viewed as a high risk investment in the management department.
My overall take is we may well succeed in spite of Nader because of the disruptive nature of LL. Maintaining valuation given the reality of the timelines presented on today’s CC will be a challenge over the remainder of the year. Nader was left with the truth today. He decided to go all in on the previous CC w the MHRA EAU pitch and suffered the consequences today.
My entire bet at this point is on the S/C trial. If we do not succeed in the Covid space it will be years to get back to a double digit SP w HIV, Cancer, or any other indication.
The SP over the coming months will align w the new timelines and risk associated w the changing Covid landscape.
Market Data 
Markets 
AI
